After nearly 20 years in academia, Collin Ewald left his position as an Assistant Professor at the ETH Zurich to join the recently formed Diseases of Aging and Regenerative Medicine, or DARe, group at Novartis. Ewald has spent his career researching the basic mechanisms that cause – and have the potential to slow – aging. Now he’s combining his expertise with that of the drug discovery teams at Novartis to find medicines that help people stay fitter and healthier throughout their old age.

By K.E.D. Coan
Published on 29/05/2024